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BACKGROUND: This study evaluates the relation of the early oestrogen-regulated gene gabarapl1 to cellular growth and its prognostic
significance in breast adenocarcinoma.
METHODS: First, the relation between GABARAPL1 expression and MCF-7 growth rate was analysed. Thereafter, by performing
macroarray and reverse transcriptase quantitative-polymerase chain reaction (RT–qPCR) experiments, gabarapl1 expression was
quantified in several histological breast tumour types and in a retrospective cohort of 265 breast cancers.
RESULTS: GABARAPL1 overexpression inhibited MCF-7 growth rate and gabarapl1 expression was downregulated in breast tumours.
Gabarapl1 mRNA levels were found to be significantly lower in tumours presenting a high histological grade, with a lymph node-
positive (pNþ) and oestrogen and/or progesterone receptor-negative status. In univariate analysis, high gabarapl1 levels were
associated with a lower risk of metastasis in all patients (hazard ratio (HR) 4.96), as well as in pNþ patients (HR 14.96).
In multivariate analysis, gabarapl1 expression remained significant in all patients (HR 3.63), as well as in pNþ patients (HR 5.65).
In univariate or multivariate analysis, gabarapl1 expression did not disclose any difference in metastasis risk in lymph node-negative
patients.
CONCLUSIONS: Our data show for the first time that the level of gabarapl1 mRNA expression in breast tumours is a good indicator of
the risk of recurrence, specifically in pNþ patients.
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Breast cancer is the most frequently diagnosed cancer among
women worldwide, with more than 1.3 million cases each year. The
understanding of this disease has progressed considerably and its
prognosis has improved because of earlier diagnosis, the
introduction of appropriate strategies and the use of novel active
treatments (Aapro, 2001; Sasco et al, 2003). However, as the
tumour-node–metastasis (TNM) stage provides scant information
on the growth pattern of each tumour, a large number of new
biomarkers have been analysed to predict the risk of recurrence
and to help apply the best adjuvant therapy. In this view, we
paid attention to a recently identified oestrogen-regulated gene
called gabarapl1 (GABAA receptor-associated protein-like 1)o rgec1
(glandular epithelial cell 1), which is thought to have an essential
role during tumour progression (Nemos et al, 2003).
The gabarapl1 gene was originally identified as an early
oestrogen-regulated gene in cultured guinea-pig endometrial
glandular epithelial cells (GECs) (Pellerin et al, 1993). The human
gene was then characterised (GeneBank Accession No. AF087847)
and its coding sequence presents 76.8% identity with that of
gabarap (g-aminobutyric acid type A receptor-associated protein).
Indeed, gabarapl1 and gabarap genes are located on 12p12.3 and
17p13.12 human chromosomes, respectively.
The GABARAPL1 protein is composed of 117 amino acids and is
highly conserved throughout evolution, suggesting a critical
cellular function. Similar to GABARAP, GABARAPL1 is involved
in protein or vesicle intracellular transport through its interaction
with cytoskeleton elements. Some publications have suggested that
GABARAPL1 and GABARAP might also be involved in tumour
development. Indeed, it was reported that lower levels of gabarap
gene expression predict decreased survival among patients with
neuroblastoma (Roberts et al, 2004). Klebig et al (2005) showed
that an ectopic overexpression of the gabarap gene inhibits cancer
cell proliferation and tumour growth in mice. We reported
elsewhere a decrease in gabarapl1 expression in cancer cell lines
(Nemos et al, 2003).
To characterise the role of gabarapl1 in breast cancer, we
analysed the level of gabarapl1 expression in some breast tumour
samples and the effect of its induced overexpression on the growth
rate of a breast cancer cell line. We also analysed gabarapl1 mRNA
expression in a retrospective cohort of 265 breast tumour biopsy
samples using a reverse transcriptase–quantitative polymerase
chain reaction (RT–qPCR) protocol to estimate its potential
prognostic effect.
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Experimental analysis
Cell transfection Human breast cancer cells (MCF-7) were
maintained as previously described (Berthier et al, 2007). The
gabarapl1 coding sequence flanked by two tag sequences coding
for a Flag peptide and a six-histidine tail was cloned into a
pcDNA3.1 Hygro( ) vector (Invitrogen, Carlsbad, CA, USA). This
construct was called pcDNA3.1-Flag-GEC1-(His)6. MCF-7 cells
were transfected with 40mg of pcDNA3.1-Flag-GEC1-(His)6 or
pcDNA3.1 control vector, and 40ml of TransFast reagent (Promega,
Madison, WI, USA) according to the manufacturer’s protocol.
The selection of resistant cells was carried out for 20 days with
200mg/ml hygromycin starting 24h after transfection until single
colonies could be picked.
Western blot analysis Whole-cell lysates (40mg) were loaded on a
12% SDS–PAGE and a western blot analysis was performed
according to the standard protocol (Towbin et al, 1979). A
monoclonal anti-Flag antibody was used at 1/6000 dilution (Sigma-
Aldrich, St Louis, MO, USA). Signals were visualised using a goat
horseradish peroxidase (HRP)-coupled anti-mouse antibody
(1/20000) (PARIS, Compie `gne, France) and the ECLplus reagent
(GE Healthcare Life Sciences, Pittsburgh, PA, USA) according to
the manufacturer’s protocol. Three independent experiments were
performed for each cell lysate.
Cell proliferation assay MCF-7-Flag-GEC1-(His)6 (clones 1 and 2)
and MCF-7-pcDNA cell lines were plated in 96-well plates (3000
cells per well) and cell proliferation experiments were conducted
over a 10-day period using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) (Sigma-Aldrich) (Morel
et al, 2007). For each clone, two independent experiments were
performed in 16 wells. Data are means±s.d. and differences
between clones were assessed using the Wilcoxon test (R software
version 2.7.1, http://cran.r-project.org).
Macroarray experiment The macroarray experiment was per-
formed using a cancer profiling array II membrane (Clontech, Palo
Alto, CA, USA). A 319-bp gabarapl1 probe, specific for the 30
mRNA untranslated region, was prepared as previously described
(Nemos et al, 2003). A volume of 50ng of gabarapl1 probe was
denaturated (10min at 951C) and randomly labelled (1h at 251C)
with 50mCi of a[
32P]-dCTP (Random Primer DNA Labelling
System; Invitrogen). The membrane was incubated overnight with
the gabarapl1 probe according to the manufacturer’s protocol,
exposed for 30h in a Storm 840 PhosphorImager (Molecular
Dynamics, Sunnyvale, CA, USA) and signals were quantified using
ImageQuant TL v2005 software (GE Healthcare Life Sciences). For
macroarray normalisation, the membrane was stripped according
to the manufacturer’s protocol and hybridised with a control
32P-labelled ubiquitin probe.
Clinical analysis
Patients and tumour characteristics Patients treated in three
medical centres (Centre Hospitalier Re ´gional Annecy, Chirurgie
Oncologique Centre Hospitalier Universitaire Lyon-Sud and
Clinique Mutualiste Saint Etienne, France) were included between
October 1994 and October 2001 (n¼265; Table 1). Patients were
selected according to the following criteria: primary breast tumour
without inflammatory features, no previous treatment and no
evidence of distant metastasis at the time of diagnosis (Descotes
et al, 2008). The median age at primary surgery was 53 years
(range 29–89). The tumour type was determined according to the
UICC-WHO criteria (Sobin and Wittekind, 1997) and histological
grading was scored according to the Scarff Bloom and Richardson
classification (Bloom and Richardson, 1957) only in the ductal
carcinomas that represented the majority (81.5%) of cases.
Oestrogen receptor (ER) and progesterone receptor (PgR)
were assayed in cytosol using the radioligand reference method
(EORTC, 1980). Quality control was based on regular testing
of both European Organization for Research and Treatment
of Cancer (EORTC) and internal controls. Results were expressed
as fmol per mg cytosol protein. ER- and PgR-positive tumours
contained 42 and 45fmol per mg protein, respectively.
All patients received locoregional radiotherapy. The majority
of node-positive patients and high-risk node-negative patients
(age of o35 years, pathological size 420mm, histological grade
of X2 and steroid receptor-negative status) received chemo-
therapy. Almost all ER-positive patients were given hormone
treatment.
Table 1 Characteristics of the studied population
All
patients
pN0
patients
pN+
patients
N¼265 N¼126 N¼139
Characteristics n % n % n %
Age (years)
o47 71 26.8 30 23.8 41 29.5
47–53 62 23.4 31 24.6 31 22.3
53–64 67 25.3 26 20.6 41 29.5
464 65 24.5 39 31.0 26 18.7
Menopausal status
Pre 111 41.9 51 40.5 60 43.2
Post 154 58.1 75 59.5 79 56.8
Surgical tumour size
pT1 114 43.0 70 55.6 44 31.7
XpT2 139 52.5 52 41.3 87 62.6
ND 12 4.5 4 3.2 8 5.8
Histological type
Lobular 39 14.7 18 14.3 21 15.1
Ductal 216 81.5 99 78.6 117 84.2
Others 10 3.8 9 7.1 1 0.7
Lymph node status
0 126 47.5 126 100.0
1–3 83 31.3 83 59.7
43 56 21.1 56 40.3
SBR grade in ductal carcinoma
1 31 14.4 17 17.2 14 12.0
2 114 52.8 58 58.6 56 47.9
3 57 26.4 22 22.2 35 29.9
ND 14 6.5 2 2.0 12 10.3
ER status
Positive 222 83.8 108 85.7 114 82.0
Negative 43 16.2 18 14.3 25 18.0
PgR status
Positive 208 78.5 106 84.1 102 73.4
Negative 57 21.5 20 15.9 37 26.6
Adjuvant systemic therapy
None 25 9.4 25 19.8 0
Hormone therapy 90 34.0 76 60.3 14 10.1
Chemotherapy 33 12.5 10 7.9 23 16.5
Hormone and chemotherapy 117 44.2 15 11.9 102 73.4
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obtained by surgery, selected by the pathologist and immediately
stored in liquid nitrogen until processing. The biopsy samples
were pulverised using a ‘Mikro-Dismembrator’ (B. Braun Biotech
International, Melsungen, Germany) and total RNAs were
extracted using TRI Reagent (Sigma). To remove any genomic
DNA contamination, total RNAs were treated with RNAse-free
DNAse I and purified using RNeasy microcolumns (Qiagen,
Hilden, Germany). RNA quality was verified using an Agilent
Bioanalyser 2100 (Agilent Technologies, Santa Clara, CA, USA). A
volume of 500ng of total RNAs was reverse transcribed using
M-MLV RT RNase H Minus reverse transcriptase and oligo(dT)15
primer following the manufacturer’s instructions (Promega). All
cDNA amplifications were performed using 1/20th of the reverse
transcription products and the LC Fast Start DNA Master SYBR
Green kit (Roche Applied Science, Basel, Switzerland), in the
presence of 3mM MgCl2 and 0.4mM of each gabarapl1 primer.
Quantitative PCR was run on a LightCycler instrument (Roche
Applied Science) with the following parameters: 10min at 951C for
the initial denaturation step, followed by 15s at 951C, 6s at 601C
and 12s at 721C per cycle for a total of 40 cycles. The gabarapl1
primers used (forward: 50-TTTGGTGCCCCTTATCTCAC-30;
reverse: 50-GGCCATCATGTAGCATTCCTT-30) for amplification
of a 241-bp fragment (GenBank AF287012) were designed using
the Primer3 software (http://fokker.wi.mit.edu/primer3/
input.htm). The amplified cDNA concentration was evaluated
using an external curve of standard samples and specific
amplification was checked using a melting curve. The PCR kinetics
and quantitative data were determined using LightCycler software
4.05 (Roche Applied Science). The gabarapl1 target concentration
was expressed relative to the concentration of the gapdh house-
keeping gene. The forward primer (50-CGACCACTTTGTCAAGCT
CA-30) and the reverse primer (50-AGGGGAGATTCAGTGTGGTG-30)
gave an amplification product of 203bp (GenBank NM_002046).
Quality control was assessed using regular testing of two
internal controls. Interassay variations were o5% (data
not shown).
Statistical analysis The median follow-up at the time of analysis
was 54 months (range 2–109). The criterion for statistical analyses
was metastasis-free survival (MFS), that is, the delay between the
time of primary surgery and the first event: nodal or distant
metastasis, or death. Neither local recurrence nor occurrence of a
contralateral cancer was taken into account, nor a second primary
cancer if it occurred within 2 years. Patients alive without
metastasis were censored at the last follow-up date. Analysis of
the distribution of gabarapl1 expression in relation to usual
prognostic parameters was performed using the Mann–Whitney
or Kruskall–Wallis test. Survival probabilities were estimated
using Kaplan–Meier estimates and were compared using the log-
rank test. Univariate and multivariate analyses were performed
using the Cox proportional hazard model. When gabarapl1 was
used as a continuous variable, we used the transformed variable
log(1/gabarapl1), which therefore provided an easier interpreta-
tion of the hazard ratio (HR). Multivariate analyses were
performed in a stepwise forward manner. A basal model in-
cluding the clinical, pathological and biological variables (except
gabarapl1) associated with prognosis was first built. The
histological grade that was determined only in ductal carcinomas
but not in lobular carcinomas could not be introduced in the basal
model. The variables were adjusted for age. The prognostic value
of gabarapl1 was tested after adding this variable to the basal
model and the significance of each variable was calculated by
comparing nested models using the likelihood ratio (LR) test.
Trend tests were performed for ordinal variables. All tests were set
at the significance level of a¼0.05. Confidence intervals (CI)
referred to the 95% level. These analyses were performed with the
R software (release 2.7.1).
RESULTS
Effect of GABARAPL1 overexpression on MCF-7 growth
rate
Previous data have shown that gabarapl1 mRNA is ubiquitously
expressed in human tissues (Nemos et al, 2003), but surprisingly
low levels were detected in some cancer cell lines, particularly in
the MCF-7 breast cancer cell line (data not shown). Therefore, we
speculated whether the ectopic expression of GABARAPL1 might
modify the growth rate of these cells. To find a solution, we
designed a stable MCF-7 cell line overexpressing the double-tagged
Flag-GEC1-(His)6 protein. Among the hygromycin-resistant colo-
nies, 20 clones were selected and GABARAPL1 protein expression
was quantified by western blotting. As shown in Figure 1A, high
GABARAPL1 levels were observed in clones 1 and 2 when
compared with the control cell line. To assess whether over-
expression of GABARAPL1 regulated the growth rate of breast
cancer cells, we performed a kinetic viability assay (MTT) using
wild-type MCF-7, MCF-7-pcDNA3.1 and two MCF-7-Flag-GEC1-
(His)6-expressing clones. As shown in Figure 1B, GABARAPL1-
expressing clones 1 and 2 showed significantly reduced growth
rates over 8 days of culture when compared with control cell lines.
Gabarapl1 expression in normal and tumour breast tissues
As GABARAPL1 overexpression was associated with a decreased
cancer cell growth rate, it can be expected that its expression might
also be altered in tumour tissues. To test this hypothesis, we
analysed gabarapl1 expression in paired normal and tumour
tissues using a cancer profiling array (Figure 2A). A dysregulation
of gabarapl1 expression was found not only in breast tumours
but also in several other types of tumours such as kidney,
testis, bladder, pancreas and prostate (data not shown). After
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Figure 1 GABARAPL1 overexpression negatively regulates the growth
rate of MCF-7 cells. (A) Western blot analysis of MCF-7-pcDNA3.1
(control) and MCF-7-Flag-GEC1-(His)6 (clones 1 and 2) cells using an anti-
Flag antibody. (B) Growth rate of MCF-7 (m), MCF-7-pcDNA3.1 (’) and
MCF-7-Flag-GEC1-(His)6 clones 1 (o) and 2 ( ) using an MTT assay.
*Po0.05 (Wilcoxon’s test).
Gabarapl1 expression and outcome in breast cancer
A Berthier et al
1026
British Journal of Cancer (2010) 102(6), 1024–1031 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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expression in tumour breast tissues were confirmed: a down-
regulation was detected in 7 out of 10 breast tumours (Figure 2B).
Gabarapl1 expression in 265 breast cancer cases
To evaluate the significance of the macroarray data obtained on 10
breast tumours, we analysed gabarapl1 expression in a cohort of
265 breast tumour biopsy samples. The mean gabarapl1 value
measured by RT–qPCR was 5.03 and the median was 4.54 (range
0.16–17.27). Table 2 shows the median value of gabarapl1 in
relation to several tumour characteristics that are usually linked to
prognosis. Indeed, in the whole population, the median gabarapl1
expression was significantly different in relation to surgical size,
histological grade, lymph node, ER and PgR status. The
histological type, ductal or lobular, revealed no difference. A
lower gabarapl1 expression was significantly related to tumour size
of 420mm only in the whole population and in the pNþ subset.
It may be observed that the median values were significantly
lower in the pejorative categories of tumours. Therefore, after
testing that the gabarapl1 distribution was log normal (data not
shown), for studies requiring a dichotomy of the variable, the
cutoff value (6.56) was found to be equal to the upper threshold of
the third quartile, allowing a discrimination between high and low
gabarap1l expression status.
Univariate analysis
Results of the univariate MFS analysis (Table 3) show the relation
between gabarapl1 expression levels and common prognostic
factors: low levels were associated with pejorative prognostic
factors. As usually observed, age and surgical tumour size were
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Figure 2 Macroarray hybridisation and analysis. Autoradiography of the membrane hybridised with (A) gabarapl1 or ubiquitin probe. (B) Normalised
gabarapl1 expression using the ubiquitin signal in normal (white bars) and tumoural breast tissues (black bars). The tumours at different stages correspond to
infiltrating ductal carcinomas (1, 2, 4, 7, 8, 9, 10), mucinous adenocarcinoma (3), Paget’s disease (5) and lobular carcinoma (6).
Table 2 gabarapl1 expression in relation to the usual prognostic factors
All patients pN0 patients pN+ patients
N¼265 N¼126 N¼139
Characteristics n Median P-value n Median P-value n Median P-value
Surgical tumour size
pT1 114 5.41 70 5.85 44 4.90
XpT2 139 3.90 52 4.68 87 3.55
ND 12 o0.001 4 0.212 8 0.013
Histological type
Ductal 216 4.34 99 5.23 117 3.90
Lobular 39 5.34 18 6.27 21 4.71
Others 10 0.076 9 0.218 1 0.231
Histological grade
a
1 31 5.52 17 5.52 14 5.48
2 114 4.96 58 6.12 56 4.33
3 57 2.96 22 2.95 35 3.09
ND 14 o0.001 2 o0.001 12 o0.001
Node status
pN0 126 5.55
pN+ 139 4.01 o0.001
ER and PgR status
ER and PgR positive 191 5.08 97 6.07 94 4.50
ER and/or PgR negative 74 3.24 o0.001 29 3.28 0.002 45 3.21 0.002
aHistological grade defined only in ductal carcinoma. P-values correspond to Mann–Whitney test or Kruskall–Wallis test (histological grade).
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pNþ subset, but not in pN0 patients. In the whole population,
lymph-node status was correlated with risk of metastasis (HR 3.67,
Po0.001). It was also observed that the risk of metastasis in
relation to low gabarapl1 levels increased by 4.96-fold in the whole
population (CI 2.43–10.12; Po0.001) and by 14.96-fold in the
pNþ subset (CI 4.80–46.60; Po0.001). In pN0 patients, gabarapl1
expression was not related to risk of metastasis.
Kaplan–Meier curves were constructed after segmentation
into two groups on the basis of the gabarapl1 expression cutoff
(Figure 3). It was observed that high values of gabarapl1
expression were related to a good prognosis. They were predictive
of longer MFS in all patients (Figure 3A, Po0.001) and in pNþ
patients (Figure 3B, Po0.001) but not in pN0 patients (data not
shown). It is noteworthy that, in the high gabarapl1 pNþ
subgroup, only one patient relapsed.
Multivariate analysis
In the whole population, the multivariate analysis applied
to the basal model (Table 4) showed, as expected, a significantly
higher risk of metastasis associated with surgical tumour size of
420mm (HR 3.00; P¼0.002), lymph node-positive status (HR
2.93; P¼0.002) and ER and/or PgR-negative status (HR 2.15;
P¼0.007).
In pNþ patients, surgical tumour size of 420mm (HR 3.59;
P¼0.004) and ER- and/or PgR-negative status (HR 2.92; P¼0.001)
were significantly related to higher metastasis risk, whereas none
of these factors were related to the risk of metastasis in pN0
patients. When gabarapl1 expression was included in this
basal model, low gabarapl1 values were associated with an
increased metastasis risk by 3.63-fold in the whole population
(CI 1.48–8.93, P¼0.005) and by 5.65-fold in the pNþ subset
(CI 1.84–17.29, P¼0.002). It is observed that in pN0 patients, the
risk of metastasis was not significantly related to gabarapl1
expression levels.
DISCUSSION
In this study, we provide for the first time an insight into the effect
of GABARAPL1 overexpression in breast cancer cells and into the
effect of gabarapl1 expression level in a large retrospective cohort
of breast tumours.
We have reported that GABARAPL1 is able to bind to tubulin
and could be involved in the transport of the GABAA receptor
(Mansuy et al, 2004). It also has an important role in the transport
of other receptors such as the k-opioı ¨d receptor (Chen et al, 2006).
Nevertheless, gabarapl1 mRNA is widely distributed in human
tissues (Nemos et al, 2003), suggesting that GABARAPL1 protein is
not only involved in the transport of receptors but probably has a
more complex role in cells. Particularly, it could be involved in cell
cycle regulation, as it interacts with tubulin (Mansuy et al, 2004).
Our study showed that MCF-7 cells overexpressing GABARAPL1
Table 3 Cox univariate analysis for metastasis-free survival
All patients (n¼265) pN0 patients (n¼126) pN+ patients (n¼139)
Characteristics HR CI P-value HR CI P-value HR CI P-value
Age (years)
o48 3.22 1.50–6.93 6.29 0.73–54.16 2.42 1.06–5.54
48–53 1.30 0.55–3.09 2.18 0.20–24.09 1.06 0.42–2.69
54–64 0.67 0.26–1.69 1.76 0.16–19.64 0.42 0.15–1.15
464 1.00 o0.001 1.00 0.202 1.00 o0.001
Menopausal status
Pre 1.65 0.97–2.82 3.60 0.93–13.97 1.40 0.77–2.52
Post 1.00 0.066 1.00 0.064 1.00 0.271
Surgical tumour size
pT1 1.00 1.00 1.00
XpT2 3.64 1.83–7.25 0.001 1.80 0.50–6.44 0.365 3.57 1.50–8.45 0.004
Histological type
Lobular 1.00 1.00 1.00
Ductal 0.95 0.47–1.95 0.895 1.99 0.25–15.76 0.516 0.81 0.38–1.75 0.592
Lymph node status
pN0 1.00
pN+ 3.67 1.85–7.30 o0.001
Histological grade
a
1 1.00 1.00
2 6.06 0.82–44.93 0.80 0.09–7.21
3 10.90 1.46–81.46 0.004 1.71 0.19–15.44 0.494 NA
b
ER and PgR status
ER and PgR positive 1.00 0.001 1.00 0.261 1.00 o0.001
ER and/or PgR negative 2.47 1.44–4.23 0.31 0.04–2.42 3.43 1.89–6.23
Gabarapl1 status
Log (1/gabarapl1)
c 4.96 2.43–10.12 o0.001 1.32 0.20–8.92 0.777 14.96 4.80–46.60 o0.001
Abbreviations: HR¼hazard ratio; CI¼confidence interval; ER¼ oestrogen receptor; PgR¼progesterone receptor. P-values correspond to Cox regression model.
aHistological
grade defined only in ductal carcinoma.
bNo events in histological grade 1 tumour subset.
cHR for an increase of one log (1/gabarapl1).
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control cell lines. This finding was in favour of a potential role of
GABARAPL1 in the control of cell proliferation as previously
reported for GABARAP overexpression in CAL51 cells (Klebig
et al, 2005). These data suggested that gabarapl1 expression could
be altered in rapidly growing breast tumour tissues. In fact, in the
macroarray experiment, most breast tumour tissues presented
weaker gabarapl mRNA levels than did normal tissues. These
results concorded with previous findings in breast cancer cell lines,
in which very low levels of gabarapl1 mRNAs were observed (data
not shown). Experiments are needed to determine whether somatic
mutations (Tomlinson, 2001) or epigenetic events (Lo and
Sukumar, 2008) are responsible for the gabarapl1 downregulation
in these cell lines.
Gabarapl1 expression has been analysed in this study for the
first time in a retrospective cohort of 265 breast tumours. The data
obtained during this investigation showed that gabarapl1 expres-
sion is significantly different in relation to usual prognostic criteria
such as tumour size, lymph-node and steroid receptor status. It is
also shown that gabarapl1 expression median values are different
in relation to tumour oestrogen and progesterone receptor status:
the median is higher in ER- and PgR-positive tumours, in
agreement with Mansuy et al (2004) who showed that gabarapl1
is an oestrogen-regulated gene.
Furthermore, we showed that tumours expressing low levels of
gabarapl1 were observed to be significantly associated with high
risk of metastasis in the pNþ subset (HR¼14.96, Po0.001) but
not in pN0 patients (Table 3). In the whole population, Kaplan–
Meier curves (Figure 3A) showed that after 80 months of follow-
up, only 3 out of 25 patients showing high gabarapl1 levels
presented a recurrence compared with 51 out of 77 patients with
low gabarapl1 levels. In the pNþ subset (Figure 3B), 1 out of 16
patients with a high gabarapl1 level relapsed, compared with 43
out of 58 with a low gabarapl1 level. These data clearly show that
the gabarapl1 expression level is negatively correlated with the risk
of metastasis.
In this study, the difference in gabarapl1 expression
between ductal and lobular types, which show different growth
patterns, is not significant. It can be observed that the median
gabarapl1 level is higher in lobular tumours, which are known to
be less aggressive than ductal ones (Table 2). The difference in
gabarapl1 expression between both types is not significant, but it
can be observed that the number of lobular tumours is very small.
Moreover, we found a significant correlation between gabarapl1
expression and the other pathological features related to prognosis,
such as tumour size, histological grade, lymph node and ER and
PgR status.
Previous results using RT–qPCR analysis on 235 neuroblasto-
mas showed that lower GABARAP expression levels were
associated with more advanced stages (Roberts et al, 2004).
Moreover, tissue microarray experiments revealed a significant
reduction in GABARAP protein expression in a high proportion of
93 breast cancers cases (Klebig et al, 2005). However, no
correlation was observed between loss of GABARAP expression
and clinicopathological features such as grading, tumour size,
oestrogen receptor status and age of diagnosis. In the latter
publication, the researchers used a polyclonal anti-GABARAP
antibody (Alpha Diagnostics, San Antonio, TX, USA) to perform
immunostaining of tissue microarrays. However, we have reason
to believe that no commercially available antibody is able to clearly
distinguish between GABARAP and GABARAPL1 proteins because
of their high degree of identity. Indeed, all the polyclonal
commercial and homemade antibodies we have tested so far in
the laboratory recognised both GABARAPL1 and GABARAP
proteins (Mansuy et al, 2004; Tolle et al, 2008). Therefore,
immunostaining analysis is unreliable and, up to now, the unique
alternative to differentiate gabarapl1 and gabarap expression is the
use of specific RT–qPCR primers located in 30-untranslated
regions.
It can be considered that despite their high homology, gabarapl1
and gabarap are probably differently regulated during the course
of breast cancer progression. Nevertheless, it would be of great
interest to further study the expression levels of these two closely
related genes to determine whether these present the same pattern
of expression in breast cancers.
CONCLUSIONS
Our data strongly suggest that, in breast cancers, high levels of
gabarapl1 mRNA are correlated with a low risk of metastasis.
This is valid in the whole population, but specifically in lymph
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snode-positive patients (HR 5.65; P¼0.002). The gabarapl1 gene
might show an important effect on tumour progression. To our
knowledge, all publications currently available only describe the
role of GABARAPL1 protein during the intracellular transport of
receptors in the brain. Hence, this investigation is the first one
describing a new interesting function of this gene in breast tissues.
These data open up a new point of view on the importance of this
small protein called GABARAPL1 in different pathways and tissues
and offer a great potential for this gene as a novel prognostic
indicator for patients developing breast cancer.
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